CTRI/2012/03/002520招募中2 期
A Multicenter, Randomized, Investigator Blind, Parallel Group, Three Arm Pilot Study To Evaluate The HPA Axis Suppression, Efficacy And Safety Of Clobetasol Propionate Cream 0.025% Formulation 5 And Clobetasol Propionate Cream 0.025% Formulation 13 As Compared To Temovate E Emollient 0.05% (clobetasol propionate emollient cream) In Patients With Moderate To Severe Psoriasis For 28 Days
Dr Reddys Laboratories0 个研究点目标入组 90 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Male and female patients of at least 18 years of age, with a clinical diagnosis of moderate to severe psoriasis.
- •2.Patient must have moderate to severe psoriasis with at least 25% Body Surface Area (BSA) involvement at Screening and Baseline. The patient can have involvement on scalp, face, groin, axillae, and/or other intertriginous areas but the 25% should not include these areas.
- •3.Patients must have Psoriasis Global Assessment (PGA) score of at least 3 (moderate) or more at Screening and Baseline for the overall disease severity.
- •4.Patients whose results from the Screening cortisol response test that are considered normal and show no evidence of any abnormal HPA function or adrenal response (screening visit ACTH test).
- •5.Female, if of child bearing potential -
- •a.Must use efficacious and reliable method of contraception during the entire duration of the study {e.g. double barrier methods (e.g., condom and spermicide); IUD} or remain sexually inactive throughout the study.
- •b.Must have a negative urine pregnancy test at Screening and Baseline (test must have a sensitivity of at least 25mIU/ml for hCG).
- •c.Must be non-lactating.
- •6.Patients must demonstrate their willingness to participate in the study and comply with the study procedures and required visits.
- •7.Have the ability to understand and sign a written informed consent form, which must be completed prior to study specific tasks being performed.
- •8.Must be willing to authorize use and disclosure of protected health information collected for the study.
排除标准
- •1.Females who are pregnant or lactating or planning to become pregnant during the study period.
- •2.Patients with known hypersensitivity to clobetasol propionate or Temovate E® or any of the ingredients of the test drugs (see Section 4)
- •3.Patients who have used any corticosteroid within 4 weeks of the Screening visit.
- •4.Patients with known history of acute adrenal crisis, Addisons disease or decreased adrenal output, low pituitary function, or pituitary tumors.
- •5.Patient has a history of an adverse reaction to Cosyntropin (injection) or similar test reagents.
- •6.Patients whose psoriasis involves only the scalp, face, groin, axillae, and/or other intertriginous areas.
- •7.Patient has current diagnosis of types of psoriasis other than stable plaque psoriasis (i.e. acute, guttate, erythrodermic, exfoliative or pustular psoriasis)
- •8.Patient has a history of psoriasis that has been unresponsive to topical corticosteroid therapy.
- •9.Patients taking or applying topical or systemic treatments likely to interfere with either psoriasis status or HPA axis function
- •10.Use of any of following by the patient:
- •a.Currently receiving or has received any radiation therapy, anti-neoplastic agents or immunosuppressant medication within 4 weeks prior to the first dose of study drug.
- •b.Undergone treatment with any systemic or photo antipsoriatic therapy within 8 weeks of the first dose of study drug.
- •c.Treated within 12 weeks (or five half lives whichever is less) prior to the first dose of study drug with any biological therapies for psoriasis.
- •d.Used any topical antipsoriatic agents of any kind or any topical corticosteroids for any reason within 2 weeks prior to Screening visit.
- •11.In the Investigators opinion, the patient has other dermatological conditions, such as atopic or contact dermatitis, that may interfere with the clinical assessments of the signs and symptoms of psoriasis
- •12.Patients with a serious and/or uncontrolled medical condition (chronic or active liver disease, renal impairment, heart disease, diabetes, severe respiratory disease, rheumatoid arthritis, current malignancies, immunocompromised conditions or any other disease) that in the opinion of the investigator would interfere with the study or place the patient at unacceptable risk.
- •13.Patients with a history or examination findings of alcohol dependence, alcohol or drug abuse or suspected abuse.
- •14.Patients who have participated in a study of an investigational drug 30 days prior to the Screening Visit.
研究者
相似试验
已完成
2 期
A clinical study to evaluate and compare the effects of three drug formulations, Tazarotene microsphere cream, Differin gel and Tazorac cream when applied topically in patients with facial acneCTRI/2009/091/000782Promius Pharma90
进行中（未招募）
1 期
Evaluation of the efficacy and safety of a new formulation (Cream) for the treatment of psoriasis vulgaris in adults as compared to a product already availible on the market and placebo.EUCTR2018-001970-66-CZMC2 Therapeutics Ltd.490
进行中（未招募）
1 期
Evaluation of the efficacy and safety of a new formulation (Cream) for the treatment of psoriasis vulgaris in adults as compared to a product already availible on the market and placebo.EUCTR2018-001970-66-DEDrug Delivery SolutionsLtd (Part of MC2 Therapeutics)490
进行中（未招募）
1 期
A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects with Chronic Inflammatory Demyelinating PolyradiculoneuropathyChronic inflammatory demyelinating polyradiculoneuropathy (CIDP)MedDRA version: 21.1Level: PTClassification code 10057645Term: Chronic inflammatory demyelinating polyradiculoneuropathySystem Organ Class: 10029205 - Nervous system disordersEUCTR2016-002411-17-BECB Biopharma SR34
已完成
2 期
A Multicenter, Randomized, Subject-Blind, Investigator-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy, Safety, and Tolerability of Rozanolixizumab in Subjects with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)10012303NL-OMON48909CB Biopharma SPR5